ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternating Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-risk Newly Diagnosed Multiple Myeloma

Inclusion Criteria: 1. Documented multiple myeloma satisfying the International Myeloma Working Group (IMWG) diagnostic criteria36 (evidence of myeloma defining event attributed to underlying plasma cell disorder) with measurable disease defined as: 1. Clonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy proven plasmacytoma 2. Measurable disease within the past 4 weeks defined by any of the following: * IgG myeloma: Serum monoclonal protein ≥ 1.0 g/dL or urine monoclonal protein ≥ 200 mg/24 hr; or * IgA, IgM, IgD, IgE multiple myeloma: serum M-protein ≥ 0.5…